https://www.prognyx.com/blog/daraxonrasib-reportedly-reaches-fda-review-in-pretreated-pancreatic-cancer-an-orPrognyxen2026-07-24Daraxonrasib reportedly reaches FDA review in pretreated pancreatic cancer — an oral RAS(ON) multi-selective inhibitor at the filing stage